Colin Ip

Colin Ip

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
CRCarolina Francelin Rovarotto
Carolina Francelin Rovarotto
SMSayak K. Mitter
Sayak K. Mitter
QQQingwen Qian
Qingwen Qian
SBSandeep Barodia
Sandeep Barodia
CIColin Ip
Colin Ip
Michael E. BoultonMichael E. Boulton
Michael E. Boulton
BACE1 is a key enzyme facilitating the generation of neurotoxic β-amyloid (Aβ) peptide. However, given that BACE1 has multiple substrates we explored the importance of BACE1 in the maintenance of retinal pigment epithelial (RPE) cell homeostasis under oxidative stress. Inhibition of BACE1 reduced mitochondrial membrane potential, increased mitochondrial fragmentation, and increased cleaved caspase-3 expression in cells under oxidative stress. BACE1 inhibition also resulted in significantly lower levels of mitochondrial fusion proteins OPA1 and MFN1 suggesting a higher rate of mitochondrial fission while increasing the levels of mitophagic proteins Parkin and PINK1 and autophagosome numbers. In contrast, BACE2 had minimal effect on cellular response to oxidative stress. In summary, our results emphasize the importance of BACE1 in augmenting cellular defense against oxidative stress by protecting mitochondrial dynamics.

1 March 2023 in Journal of Cataract & Refractive Surgery
Verified
Journal Article
Closed access
CIColin Ip
Colin Ip
DJD. Kyle Jones
D. Kyle Jones
EWEric Weinlander
Eric Weinlander
BGBrett Gudgel
Brett Gudgel
ALAmy Lin
Amy Lin
MMMark D. Mifflin
Mark D. Mifflin
Purpose: To evaluate the safety and efficacy of processed amniotic fluid (pAF) used postoperatively after photorefractive keratectomy (PRK). Setting: University of Utah, Moran Eye Center, Salt Lake City, Utah. Design: Randomized, double-masked, placebo-controlled prospective study. Methods: 61 participants were randomized to receive either placebo or pAF drops, which were instilled 4 times per day for 1 week after PRK along with routine postoperative medications. The primary outcome measure was time to full re-epithelialization in days. Secondary measures included visual acuity at 30 days and postoperative pain scores during the first week. Results: There was no significant difference in time to re-epithelialization, with a median of 5 days for both groups. There were no difference in pain indicator scores during the first week and no difference in corneal staining scores at day 30 between the 2 groups. There were no adverse events. Conclusions: This pilot study evaluating the safety and efficacy of pAF as an additional postoperative topical medication for PRK demonstrated that pAF did not improve the rate of epithelial healing after PRK. pAF may be safely studied in other ocular conditions to determine its effect on epithelial healing.